User profiles for David Cella
 | David CellaProfessor, Northwestern University Verified email at northwestern.edu Cited by 167136 |
The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks …
OBJECTIVES: Patient-reported outcomes (PROs) are essential when evaluating many new
treatments in health care; yet, current measures have been limited by a lack of precision, …
treatments in health care; yet, current measures have been limited by a lack of precision, …
Psychometric evaluation and calibration of health-related quality of life item banks: plans for the Patient-Reported Outcomes Measurement Information System …
Background: The construction and evaluation of item banks to measure unidimensional
constructs of health-related quality of life (HRQOL) is a fundamental objective of the Patient-…
constructs of health-related quality of life (HRQOL) is a fundamental objective of the Patient-…
The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years
Background: The National Institutes of Health (NIH) Patient-Reported Outcomes
Measurement Information System (PROMIS) Roadmap initiative (www. nihpromis. org) is a 5-year …
Measurement Information System (PROMIS) Roadmap initiative (www. nihpromis. org) is a 5-year …
The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT‐G) in patients with …
…, CA Meyers, CK Gelke, KS Byrne, VA Levin, DF Cella - Cancer, 1995 - Wiley Online Library
Background. This report describes the development and validation of a brain subscale for
the Functional Assessment of Cancer Therapy (FACT) scale, and the revalidation of the …
the Functional Assessment of Cancer Therapy (FACT) scale, and the revalidation of the …
[PDF][PDF] The Functional Assessment of Cancer Therapy scale: development and validation of the general measure
Purpose: We developed and validated a brief, yet sensitive, 33-item general cancer quality-of-life
(QL) measure for evaluating patients receiving cancer treatment, called the Functional …
(QL) measure for evaluating patients receiving cancer treatment, called the Functional …
Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition
GA Curt, W Breitbart, D Cella, JE Groopman… - The …, 2000 - academic.oup.com
Purpose. This survey was designed to confirm the prevalence and duration of fatigue in the
cancer population and to assess its physical, mental, social, and economic impacts on the …
cancer population and to assess its physical, mental, social, and economic impacts on the …
[PDF][PDF] Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.
MJ Brady, DF Cella, F Mo, AE Bonomi… - Journal of clinical …, 1997 - academia.edu
Purpose: This is the first published report on the vali-dation of the Functional Assessment of
Cancer Therapy-Breast (FACT-B), a 44-item self-report instrument designed to measure …
Cancer Therapy-Breast (FACT-B), a 44-item self-report instrument designed to measure …
[HTML][HTML] Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
…, EA Perez, T Shenkier, D Cella… - New England journal …, 2007 - Mass Medical Soc
Background In an open-label, randomized, phase 3 trial, we compared the efficacy and
safety of paclitaxel with that of paclitaxel plus bevacizumab, a monoclonal antibody against …
safety of paclitaxel with that of paclitaxel plus bevacizumab, a monoclonal antibody against …
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non–small cell lung cancer: a randomized trial
…, K Kelly, H Spiridonidis, A Sandler, KS Albain, D Cella… - Jama, 2003 - jamanetwork.com
ContextMore persons in the United States die from non–small cell lung cancer (NSCLC) than
from breast, colorectal, and prostate cancer combined. In preclinical testing, oral gefitinib …
from breast, colorectal, and prostate cancer combined. In preclinical testing, oral gefitinib …
[HTML][HTML] Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations
…, DN Ader, N Brandenburg, LB Burke, D Cella… - The journal of pain, 2008 - Elsevier
A consensus meeting was convened by the Initiative on Methods, Measurement, and Pain
Assessment in Clinical Trials (IMMPACT) to provide recommendations for interpreting clinical …
Assessment in Clinical Trials (IMMPACT) to provide recommendations for interpreting clinical …